GlassScriptPhysician profile
Carol R Rapson
NPI 1073513917
$10,492.95
in general payments reported to CMS, 2019-2025
77 companies · $2,342 in 2025
The $2,342 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,160 · 2020: $872 · 2021: $1,537 · 2022: $1,739 · 2023: $1,615 · 2024: $1,228 · 2025: $2,342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,839 · Education: $337 · Royalty Or License: $8.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,839.35 |
| Education | $336.67 |
| Royalty Or License | $8.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $883.25 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Amgen INC. | $787.93 | 2019-2025 | Imdelltra (Amg757), Kyprolis, Blincyto |
| Genentech USA, INC. | $784.87 | 2019-2025 | Polivy, Tecentriq, Lunsumio |
| Novartis Pharmaceuticals Corporation | $781.49 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $695.71 | 2019-2025 | Calquence, Enhertu, Lynparza |
| Pfizer INC. | $492.25 | 2019-2025 | |
| Janssen Biotech, INC. | $453.82 | 2019-2025 | Erleada, Rybrevant, Darzalex |
| Celgene Corporation | $422.47 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Takeda Pharmaceuticals U.S.A., INC. | $390.65 | 2019-2025 | Ninlaro, Alunbrig, Iclusig |
| Seagen INC. | $345.34 | 2020-2025 | Tukysa, Padcev |
| Abbvie INC. | $231.59 | 2021-2025 | |
| Genzyme Corporation | $230.48 | 2019-2025 | |
| Incyte Corporation | $224.29 | 2019-2025 | Jakafi, Monjuvi |
| E.R. Squibb & Sons, L.L.C. | $216.24 | 2019-2025 | Opdivo, Opdualag |
| Lilly USA, LLC | $212.49 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
Show all 77 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Rapson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.